SCHEMBL4674476

SCHEMBL4674476

O=C(C=C(O)c1nc[nH]n1)c1coc(Cc2ccccc2Cl)c1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR4A2 P43354 2/20 0.33
KDM4A O75164 1/20 0.33
KDM4C Q9H3R0 1/20 0.33
KDM5B Q9UGL1 1/20 0.33
NPC1 O15118 1/20 0.33
RAB9A P51151 1/20 0.33
AR P10275 1/20 0.32
NLRP3 Q96P20 1/20 0.32
CASP6 P55212 1/20 0.31
L3MBTL1 Q9Y468 1/20 0.31
CFTR P13569 1/20 0.31
LMNA P02545 1/20 0.31
HPGD P15428 1/20 0.31
LTB4R Q15722 1/20 0.31
LTB4R2 Q9NPC1 1/20 0.31
TP53 P04637 1/20 0.31
PDE3B Q13370 1/20 0.30
PDE3A Q14432 1/20 0.30
ALDH1A1 P00352 1/20 0.30
POLB P06746 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4674108 0.88 AR (0.32) KDM5BNPC1RAB9AARL3MBTL1
SCHEMBL4672199 0.86 IDH1 (0.40) AR
SCHEMBL4679296 0.86 AR (0.36) NPC1RAB9AARALDH1A1POLB
SCHEMBL4676336 0.85 AR (0.35) RAB9AARLMNAALDH1A1MAOA
SCHEMBL4672298 0.85 SMN1; SMN2 (0.34) NR4A2KDM4AKDM4CKDM5BL3MBTL1
SCHEMBL4679964 0.84 HCAR2 (0.39) NR4A2KDM4AKDM4CKDM5BLMNA
SCHEMBL5899363 0.83 ALDH1A1 (0.34) NPC1RAB9AL3MBTL1LMNAHPGD
SCHEMBL4676464 0.83 BRS3 (0.35) NR4A2KDM4AKDM4CKDM5BNPC1
SCHEMBL4675323 0.82 PTGER1 (0.37) NLRP3LMNAHPGDTP53ALDH1A1
SCHEMBL4675429 0.81 IDH1 (0.31) LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 NR4A2 454/4885KDM4A 340/4885KDM4C 785/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.